Core Viewpoint - The acceptance of the registration application for MaiLi Precise by the NMPA marks a significant milestone in the development of high-end hyaluronic acid products by East China Pharmaceutical in the Chinese market [1][4]. Group 1: Product Development and Market Position - MaiLi series is a high-end hyaluronic acid brand under East China Pharmaceutical, consisting of four products, all of which are already launched in Europe [2]. - MaiLi Precise, the product recently accepted for registration, is designed to correct under-eye hollows and has shown good filling performance and safety in clinical trials [4]. - The Chinese hyaluronic acid market is experiencing rapid growth, with a market size increase from 3.1 billion yuan in 2017 to 6.3 billion yuan in 2021, and projected to reach 44.1 billion yuan by 2030, reflecting a compound annual growth rate of 24.2% from 2021 to 2030 [4]. Group 2: Competitive Advantage and Technology - The MaiLi series avoids competition in a saturated market by leveraging its high-end brand positioning and unique OxiFree technology, which preserves long-chain hyaluronic acid and reduces the need for chemical cross-linking agents [5]. - This innovative technology allows for stronger support and a lighter, more flexible effect with less product usage, providing a safer and more effective option for consumers [5]. Group 3: Strategic Expansion and Future Outlook - East China Pharmaceutical is committed to a global operational strategy and has a comprehensive product matrix covering various aesthetic medical fields, including injectables and energy-based devices [6]. - The company is actively expanding its international market presence, with multiple products undergoing registration in regions such as the Middle East and Europe [8]. - A rich pipeline of new products is expected to launch in the coming years, including new high-end hyaluronic acid fillers and a recombinant botulinum toxin, which will further enhance the company's market position [9].

Core Viewpoint - The company Huadong Medicine (000963) announced that its wholly-owned subsidiary, Xinkelimeixue (Hangzhou) Medical Technology Co., Ltd., has received an acceptance notice from the National Medical Products Administration (NMPA) for its application to register a Class III medical device, the lidocaine injection cross-linked hyaluronic acid gel MaiLi Precise [1] Group 1 - The acceptance notice indicates progress in the regulatory approval process for the medical device [1] - The registered product, MaiLi Precise, is a cross-linked hyaluronic acid gel that includes lidocaine, suggesting a focus on aesthetic and medical applications [1] - This development may enhance the company's product portfolio and market competitiveness in the medical aesthetics sector [1]

Core Viewpoint - The company Huadong Medicine (000963.SZ) announced that its wholly-owned subsidiary, Xinkelimeixue (Hangzhou) Medical Technology Co., Ltd., has received an acceptance notice from the National Medical Products Administration (NMPA) for its Class III medical device registration application for the lidocaine injection cross-linked transparent hyaluronic acid gel MaiLi Precise [1] Group 1 - Huadong Medicine's subsidiary has successfully submitted a registration application for a new medical device [1] - The acceptance of the application indicates progress in the company's product development pipeline [1] - The product in question is a Class III medical device, which typically requires rigorous regulatory scrutiny [1]

Core Viewpoint - Huadong Medicine (000963.SZ) announced that its wholly-owned subsidiary, Xinkelimeixue (Hangzhou) Medical Technology Co., Ltd., received the Acceptance Notice from the National Medical Products Administration (NMPA) for its Class III medical device registration application for lidocaine injection cross-linked hyaluronic acid gel MaiLiPrecise [1] Group 1 - The application for MaiLiPrecise has been accepted by NMPA, indicating progress in regulatory approval [1] - MaiLi series products are high-end hyaluronic acid gel products owned by Sinclair Pharmaceuticals Limited, a wholly-owned subsidiary of the company [1] - The products are developed in collaboration with Kylane Laboratoires SA, a Swiss professional medical aesthetics R&D company, in which Sinclair holds a stake [1]

证券代码：000963 证券简称：华东医药 公告编号：2025-092 华东医药股份有限公司 关于全资子公司收到医疗器械注册申请受理通知书的公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假 记载、误导性陈述或重大遗漏。 近日，华东医药股份有限公司（以下简称"公司"）全资子公司 欣可丽美学（杭州）医疗科技有限公司收到国家药品监督管理局 （NMPA）签发的《受理通知书》，其申报的三类医疗器械含利多卡 因注射用交联透明质酸钠凝胶MaiLi Precise注册申请获得受理。现将 具体情况公告如下： 一、受理通知书相关情况 申请事项：进口医疗器械注册申请 MaiLi系列是公司英国全资子公司Sinclair Pharmaceuticals Limited （以下简称"Sinclair"）旗下的高端透明质酸钠凝胶（玻尿酸）产品， 来自于Sinclair参股的瑞士专业医美研发公司Kylane Laboratoires SA， Sinclair拥有该系列产品的全球独家许可。该产品于2020年6月获得欧 盟CE认证，并于2021年上半年在欧洲市场上市，获得了积极的市场反 第 1 页 共 3 页 馈。 Ma ...

Core Viewpoint - The announcement indicates that East China Pharmaceutical's subsidiary, Xinkeli Medical Technology Co., Ltd., has received an acceptance notice from the National Medical Products Administration for the registration application of the Class III medical device "MaiLi Precise," which is a cross-linked hyaluronic acid gel containing lidocaine. This marks a significant milestone in the product's development process in the Chinese market [1] Group 1 - The registration application for MaiLi Precise has been accepted, which is a crucial step for its market entry in China [1] - The MaiLi series products are globally licensed exclusively to East China Pharmaceutical's wholly-owned subsidiary, Sinclair Pharmaceuticals Limited [1] - The recent progress is not expected to have a significant impact on the company's short-term operating performance, but the company will continue to advance the registration and sales process domestically [1]

Core Viewpoint - The article emphasizes the importance of "five-dimensional positive growth" for companies, which includes continuous growth in total assets, operating income, net profit attributable to shareholders, R&D investment, and employee compensation from 2022 to 2024, as a measure of a company's internal motivation and sustainable development capability [2][3]. Summary by Sections Five-Dimensional Positive Growth - Companies with long-term competitiveness maintain steady growth not only in asset scale and revenue but also in innovation investment and human capital [3]. - A total of 156 companies in the A-share market meet the criteria of achieving three consecutive years of growth in the five key indicators, indicating a focus on solid asset foundations and strategic investments in R&D and employee compensation [3][4]. Industry Distribution - The 156 companies are concentrated in sectors such as machinery, electronics, power equipment, pharmaceuticals, and automobiles, highlighting the transformation and upgrading of China's manufacturing industry through technological accumulation and talent investment [4][6]. - The automotive sector leads with 30 companies, followed by power equipment (22), machinery (20), electronics (14), and pharmaceuticals (13), collectively accounting for over 63% of the group [6]. Key Industry Analysis - **Automotive**: The sector shows strong market vitality, particularly in new energy vehicles, with companies like BYD demonstrating significant growth through vertical supply chain integration and R&D investment [9]. - **Power Equipment**: Companies like Sungrow Power Supply benefit from global green energy demand, with continuous R&D ensuring technological leadership [12]. - **Machinery**: Companies such as Times Electric leverage their technological advantages to achieve growth in both domestic and international markets [13]. - **Electronics**: Firms like North Huachuang are capitalizing on domestic semiconductor expansion, with R&D driving rapid growth [15]. - **Pharmaceuticals**: Companies like Mindray Medical are expanding through continuous innovation in medical technology, supported by robust R&D investment [16]. Internal Logic of Growth - Achieving simultaneous growth in the five dimensions is challenging, with only 156 out of 5,383 A-share companies meeting the criteria by the end of 2024 [18]. - The interplay between R&D investment and human capital is crucial for maintaining competitive advantage in a rapidly evolving market [19][20]. Long-Termism and Employee Compensation - Employee compensation and R&D investment are identified as dual anchors of long-termism, with average employee compensation increasing by approximately 35% and R&D investment by about 42% from 2021 to 2024 among the 156 companies [25]. - This focus on human and innovation capital, despite potential short-term impacts on profit margins, enhances organizational stability and competitive barriers [25]. Conclusion - The article concludes that the concept of being a "respected" company should not solely rely on scale or profit but should also encompass the creation of economic value while promoting technological advancement, employee growth, and social welfare [26].

Core Viewpoint - East China Pharmaceutical announced that its wholly-owned subsidiary, Hangzhou Sino-American East China Pharmaceutical Co., Ltd., has completed the first random dosing of HDM1005 injection, a GLP-1/GIP dual-target long-acting agonist, in the Phase III clinical study for weight loss indication in China [1] Group 1 - The clinical study is identified as HDM1005-301 [1] - The drug is designed to target both GLP-1 and GIP pathways, which are significant in weight management [1] - The completion of the first random dosing marks a critical milestone in the development of HDM1005 [1]

Core Insights - The evaluation criteria for companies in China are shifting from a focus on single profit metrics to a multidimensional assessment of capabilities, emphasizing long-term competitiveness through sustained growth in assets, revenue, net profit, R&D investment, and employee compensation [1][19] - A total of 156 companies in the A-share market have met the criteria of achieving positive growth across these five dimensions for three consecutive years, indicating a robust foundation for sustainable development [1][13] Industry Distribution - The 156 companies are primarily distributed across sectors such as machinery, electronics, power equipment, pharmaceuticals, and automotive, highlighting the transformation and upgrading of China's manufacturing industry through technological accumulation and talent investment [2][5] - The automotive sector leads with 30 companies, followed by power equipment (22), machinery (20), electronics (14), and pharmaceuticals (13), collectively accounting for over 63% of the total [3][5] Key Industries and Representative Companies - **Automotive (30 companies)**: This sector includes traditional vehicles, new energy vehicles, and smart solutions, showcasing China's leadership in the global automotive industry transformation [6] - BYD (002594.SZ) has demonstrated strong growth through vertical integration and significant R&D investment, establishing a robust competitive barrier [6] - Fuyao Glass (600660.SH) has capitalized on the trend of automotive intelligence and consumer upgrades, enhancing product value and driving revenue growth [7] - **Power Equipment (22 companies)**: This sector benefits from the dual carbon strategy, with growth driven by advancements in renewable energy technologies and smart grid construction [8] - Sungrow Power Supply (300274.SZ) has seen rapid growth due to its leadership in photovoltaic inverters and energy storage systems [8] - Guoxuan High-tech (002074.SZ) focuses on battery technology, leveraging continuous investment in R&D to build a competitive edge [8] - **Machinery (20 companies)**: This sector reflects the transformation of Chinese manufacturing, with companies benefiting from domestic industrial upgrades [9] - Times Electric (688187.SH) has sustained growth through its core competencies in rail transit equipment and expansion into new industries [9] - Tiandi Technology (600582.SH) leads in intelligent coal mining equipment, achieving steady growth through technological advancements [10] - **Electronics (14 companies)**: This sector has shown significant growth, driven by demand in semiconductors, high-end components, and consumer electronics [11] - Northern Huachuang (002371.SZ) has benefited from the expansion of domestic wafer fabrication, leading to rapid revenue growth [11] - Haiguang Information (688041.SH) has established a strong presence in the domestic CPU market, capitalizing on the demand for localized computing power [11] - **Pharmaceuticals (13 companies)**: This sector is driven by aging populations and increased health awareness, with companies focusing on R&D in innovative drugs and high-end medical devices [12] - Mindray Medical (300760.SZ) has built core competencies through continuous innovation in medical technology [12] - East China Pharmaceutical (000963.SZ) is expanding its growth through innovative drug development and aesthetic medicine [12] Five-Dimensional Growth Logic - Achieving positive growth across the five dimensions is a complex task, with only 156 out of 5,383 A-share companies meeting this standard, indicating a strong correlation between R&D investment and sustainable growth [13][18] - The combination of total assets, revenue, net profit, R&D investment, and employee compensation reflects a company's health and sustainability, with each dimension interlinked [14][15][16]

登录新浪财经APP 搜索【信披】查看更多考评等级 证券代码：000963 证券简称：华东医药 公告编号：2025-090 华东医药股份有限公司 第十一届董事会第三次会议决议公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假记载、误导性陈述或重大遗 漏。 一、董事会会议召开情况 华东医药股份有限公司（以下简称"公司"）第十一届董事会第三次会议的通知于2025年10月10日以书面 和电子邮件等方式送达各位董事，于2025年10月13日（星期一）在公司会议室以现场并结合通讯方式召 开。会议应参加董事11名，实际参加董事11名。会议由公司董事长主持。会议的召开和表决程序符合 《公司法》《公司章程》的有关规定，会议合法有效。 二、董事会会议审议情况 董事会就以下议案进行了审议，经书面和通讯方式表决，通过决议如下： 审议通过《关于2022年限制性股票激励计划预留授予限制性股票第二个解除限售期解除限售条件成就的 议案》 具体内容详见公司同日披露于巨潮资讯网（http://www.cninfo.com.cn）的公司《关于2022年限制性股票 激励计划预留授予限制性股票第二个解除限售期解除限售条件成就的公 ...